Background
==========

More than two-thirds of all cancer patients will develop bone metastases \[[@b1-medscimonit-20-556]\], and thoracolumbar spinal vertebrae are more commonly affected than any other bone \[[@b2-medscimonit-20-556]\]. In the United States alone, more than 350,000 cases of spinal metastasis are reported each year due to prostate, breast, kidney, lung, and thyroid cancers \[[@b3-medscimonit-20-556],[@b4-medscimonit-20-556]\]. After invading the spinal bone, growth factors that stimulate osteoblastic and osteolytic activities are up-regulated, resulting in a cycle of bone destruction and local cancer cell proliferation that can cause symptomatic pain, mechanic instability, neurological dysfunction, sphincter control failure, hypercalcemia, and pathological fractures \[[@b1-medscimonit-20-556]\]. Furthermore, recent improvements in cancer therapy have improved survival in many cancer types, and spinal metastasis occurrence is expected to rise dramatically over the next decade with this increased life expectancy \[[@b5-medscimonit-20-556]\]. Thus, there is an urgent need for improved treatments for spinal metastases.

Recent radiosurgical techniques improved primary and adjunctive treatment of spinal metastases \[[@b6-medscimonit-20-556]\], but no technique has yet been demonstrated to dramatically improve life expectancy in these patients \[[@b7-medscimonit-20-556]\]; however, skillful medical management and advanced interventions have improved their quality of life and reduced postoperative morbidity \[[@b8-medscimonit-20-556]\]. These improvements are largely due to the wide modern implementation of palliative and conservative intervention strategies, including radiation therapy, chemotherapy, and hormonal interventions \[[@b8-medscimonit-20-556]\]. Notably, these treatments promote affected vertebra ossification, thus alleviating spinal compression and reducing the occurrence of pathological fractures \[[@b9-medscimonit-20-556]\]. Conventionally, most practitioners think that laminectomy is the only approach for spinal surgery of cancer metastases, but many minimally invasive techniques for spinal surgery have recently become available, including endoscopy, kyphoplasty or vertebroplasty, and stereotactic radiosurgery \[[@b10-medscimonit-20-556],[@b11-medscimonit-20-556]\]. While each technique is extensively reported alone, few clinical studies have documented the efficacy and safety of combinations of these methods for treating spinal metastases.

Real-time image-guided radiofrequency ablation (RFA) is a minimally invasive treatment recently developed for treating vertebral tumors, using image-guided positioning of an electrode in the lesion to kill malignant cells percutaneously with minimal damage to adjacent healthy tissues \[[@b12-medscimonit-20-556]\]. However, RFA does not alleviate nerve function or prevent pathologic fracture \[[@b12-medscimonit-20-556]\]. Consequently, RFA has recently been combined with percutaneous vertebroplasty (PVP), which involves direct injection of bone cement into the vertebra under fluoroscopic guidance, thus reconstructing the mechanical stability of the vertebral body and additionally removing remaining malignant cell or damaged nerve endings during the heated hardening process \[[@b13-medscimonit-20-556],[@b14-medscimonit-20-556]\]. However, the potentially serious complications that can be caused by extravasation of cement into foraminal, epidural, and dural spaces or paravertebral veins has limited its wide implementation \[[@b15-medscimonit-20-556]\]. Percutaneous kyphoplasty (PKP) using balloon dilatation can be used to reduce the rate of cement leakage, making these procedures safer and more effective \[[@b16-medscimonit-20-556]\].

Thus, it is hypothetically feasible to combine RFA and PKP to alleviate symptoms from vertebral tumors and to restore vertebral height with reduced risk \[[@b17-medscimonit-20-556],[@b18-medscimonit-20-556]\]. The aim of the present retrospective study was to review the efficacy and safety of this procedure in clinical thoracolumbar vertebral metastatic patients treated at a single center. These findings may provide a basis for further study of combined RFA and PKP for spinal metastases.

Material and Methods
====================

Study design
------------

We performed a retrospective study of 26 patients (M: F, 12: 14; mean age 59.31±11.62 years, range 32--75 years) was conducted, including 38 vertebral metastases at T~11~, T~12~, L~1~, L~2~, L~3~, L~4~, L~5~, and S~1~ (*n*=4, 7, 5, 8, 2, 7, 2, and 3, respectively), all with abundant blood vessels. Patients underwent image-guided RFA with PKP under general anesthesia from February 2005 to January 2009 at the Department of orthopedics, Shanghai 10^th^ People's Hospital, Tongji University School of Medicine. The study protocol was approved by the Ethics Committee of Tongji University (China), and all patients provided written informed consent for participation.

Patients
--------

Inclusion criteria were: 1) diagnosed with unresectable malignant vertebral metastasis according to the criteria provided by Tokuhashi \[[@b19-medscimonit-20-556]\]; 2) sought treatment for untreatable pain that severely affected quality of life; 3) metastatic lesion caused by pathologic fractures on X-ray images; and 4) symptoms that were not effectively alleviated by routine chemotherapy, radiation therapy, or other treatments.

Exclusion criteria were: 1) unable to tolerate surgery; 2) allergy to required anesthetics or antibiotics; 3) signs of infection at the surgical site or localized skin infection; or 4) vertebral fracture lines extending or crossing the vertebral posterior margin, vertebral bone destruction or incompletion, osteoblastic tumors, or spinal cord or nerve compression.

Preoperative preparation
------------------------

Patients underwent electrocardiography (ECG), bleeding and clotting assessment, spinal anteroposterior, 3-dimensional (3D) vertebra reconstruction, lateral X-ray imaging, and scanning with computed tomography (CT), magnetic resonance imaging (MRI), and systemic radionuclide bone scan. Patients aged \>65 years additionally completed heart and lung function assessments. Tumor location, size, and proximity to adjacent tissues/organs were examined, and anatomical examination of the pedicle was conducted. Appropriate electrode type, puncture site, and needle insertion angle were selected using these parameters, as previously described \[[@b20-medscimonit-20-556]\], and based on the operator's judgment. In case of abnormal, large, multiple, or irregularly shaped bone metastases, multiple needle punctures were required to reach the ablation range sufficient to achieve an effective 2-puncture radius overlap of 30--50%, as previously described \[[@b21-medscimonit-20-556]\]. Preoperative digital subtraction angiography (DSA) and local vascular gel foam embolization were performed when necessary.

Tumor biopsy
------------

Tumor biopsy was performed in all patients. Patients were placed in the prone position under general anesthesia. The skin around the incision was disinfected with Anerdian (Shanghai Likang Disinfectant Hi-tech Co., Shanghai, China). Unilateral or bilateral transpedicular needle insertion was conducted using CT or C-arm X-ray equipment for visualization (operative field diameter=30 cm). Using this path, a bone biopsy needle (Cook Medical, Bloomington, IN, USA) was inserted. Lesion biopsy specimens were sampled and pathologically examined using routine methods.

Surgical intervention
---------------------

Intravenous steroids were administered to all patients before surgery to prevent anaphylactic reactions to bone cement. Immediately following biopsy, an appropriately sized ablation electrode was inserted along the same path as the biopsy needle. The size of the electrode was selected according to the desired effect diameter (2.0, 2.5, or 4.0 cm). The cathode plate was affixed to the posterolateral lower limb and fully opened. Ablation was conducted continuously for 4--6 minutes at 95±5°C and 150 W, generating an effective diameter of 1.5--2.0 cm. The ablation electrode was inserted into the lesion center or adjusted for multiple ablation. The electrode was then slowly removed, and thermocoagulation was performed on the percutaneous puncture to prevent bleeding. The procedure was repeated, if necessary, based on lesion scope and size. When possible, ablation was extended 0.5--1.0 cm outside the tumor boundary, avoiding nerves, blood vessels, and vital organs ([Figure 1A, 1B](#f1-medscimonit-20-556){ref-type="fig"}).

A unilateral or bilateral balloon was implanted and inflated with a dedicated balloon pressurizer (Medtronic, Fridley, MN, USA) ([Figure 1C](#f1-medscimonit-20-556){ref-type="fig"}). Excessive dilation was avoided to prevent vertebral re-fracture and balloon rupture. A 3--5 ml (\~1.5 ml inside tube) volume of bone cement (Tianjin Synthetic Material research Institute, Tianjin, China) was slowly pushed into the vertebral cavity, filling it completely while avoiding leakage ([Figure 1D, 1E](#f1-medscimonit-20-556){ref-type="fig"}). Then, the injector and cannula were removed, avoiding cement tail formation. The incision in the percutaneous puncture site was sutured using 1 to 2 Ethicon sutures (Johnson & Johnson, New Brunswick, NJ, USA).

Postsurgical care
-----------------

Immediately after surgery, antibiotic treatments (cefradine IV, 2 g/12 h for 3 days) were administered for 3 days to prevent infection, and glucocorticoids (dexamethasone IV, 10 mg/day for 3 days, 5 mg/day on the fourth day) were administered as needed to prevent swelling. Local pain was treated with non-steroidal anti-inflammatory drugs (NSAIDs) or narcotics, including indomethacin (100 mg) suppository and bucinnazine (100 mg) intramuscular injection. Six h after disappearance of the anesthetic effect, a bolus dose of non-steroidal anti-inflammatory drug (celecoxib 200 mg or fenbid 300 mg) was administered to ease pain at the puncture site.

Follow-up
---------

Patients were followed up for a minimum of 3 months, and up to 18 months. Clinical assessments were conducted postoperatively at day 3, week 1, and months 1, 3, and 6. At each examination, visual analogue scales (VAS) scores were self-reported and recorded on a 0--10 point scale to indicate pain. Outcomes of tumor recurrence and pain levels were examined at each follow-up visit.

Efficacy assessments
--------------------

Stability outcomes were assessed by postsurgical X-ray to measure vertebral height.

Safety assessments
------------------

Complications and adverse events (AEs) at each follow-up visit were used to assess safety.

Statistical analysis
--------------------

SPSS 11.0 (SPSS, Inc., Chicago, IL, USA) was used for all data analysis. Pre- and postoperative VAS scores were compared using paired *t*-tests. *P*-values \<0.05 were considered significant (*P*\<0.05).

Results
=======

Patient demographic, clinical and surgical characteristics
----------------------------------------------------------

The number of men and women (12:14) was similar. Patients were aged 35--75 years (mean of 59.31±11.62). All patients completed a minimum of 3 months of follow-up (mean of 8.31±3.87 months). A total of 12 (46.2%) patients received analgesics and no significant differences were observed in patients who did or did not received analgesics (*P*\>0.05). Most patients (12/26, 46.2%) had 2 lesions, 13 (50.0%) patients had only 1 lesion, and only 1 (3.8%) patient had 3 lesions. The average number of lesions was 1.68±0.56 per patient. Spinal metastatic lesions were secondary to prostate cancer (5/26, 19.2%), breast cancer (6/26, 23.1%), lung cancer (3/26, 11.5%), sacrum cancer (2/26, 7.7%), kidney cancer (2/26, 7.7%), lymphoma (2/26, 7.7%), esophageal cancer (1/26, 3.9%), adenocarcinoma (1/26, 3.9%), liver cancer (2/26, 7.7%), mesenchymal cancer (1/26, 3.9%), and thyroid cancer (1/26, 3.9%) ([Table 1](#t1-medscimonit-20-556){ref-type="table"}).

A mean of 2.69±0.93 (2\~5) ablation was performed per patient. The ablation procedure required a mean of 15.08±4.64 (10\~25) min, while the injection of bone cement required a mean of 6.73±0.83 (5\~8) min, for a mean total operating time of 47.77±7.13 (36\~63) min. No balloon leakage was observed in any patient.

Postoperative efficacy outcomes
-------------------------------

RFA with PKP treatment was successful in all patients (*n*=26), and no need for secondary surgery was reported at any time point during follow-up. Minor pain was reported during postsurgical week 1, which was generally effectively alleviated by oral analgesics. No pain or other symptoms were reported after week 1. Changes in patient X-rays before and after treatment indicated improved postoperative vertebral height in all patients, indicating good clinical efficacy ([Figures 2](#f2-medscimonit-20-556){ref-type="fig"} and [3](#f3-medscimonit-20-556){ref-type="fig"}). No recurrence was reported.

Postoperative safety outcomes
-----------------------------

No treatment-related complications or adverse events occurred during or after the intervention. No symptomatic nerve damage or deaths were reported.

VAS scores indicate clinical efficacy
-------------------------------------

Mean VAS scores at baseline, 3 days, at 1 week, and at months 1, 3, and 6 were 7.69±1.12, 6.62±1.02, 4.65±1.55, 3.62±0.98, 2.77±0.82, and 2.96±0.92, respectively ([Table 1](#t1-medscimonit-20-556){ref-type="table"}, [Figure 4](#f4-medscimonit-20-556){ref-type="fig"}). The highest postoperative VAS scores were observed at day 3, reaching as high as 10. The maximum VAS score by 1 week was 7, and no VAS score higher than 5 was reported at any subsequent times. Compared to the preoperative mean VAS score (7.69±1.12), VAS score was significantly decreased at all time points (*P*\<0.01) ([Figure 4](#f4-medscimonit-20-556){ref-type="fig"}), suggesting the relief of symptoms and effectiveness of the treatment of RFA combined with PKP.

Discussion
==========

The aim of the present retrospective study was to review the efficacy and safety of RFA with PKP in clinical thoracolumbar vertebral metastatic patients treated at a single center. An assessment of 26 patients with vertebral metastases treated with RFA with PKP revealed that this treatment approach had high efficacy and good safety. No major adverse events or complications were reported, and no recurrence or secondary surgical intervention occurred during follow-up. Furthermore, pain peaked at 3 days after RFA with PKP intervention, and was then relieved because no VAS score above 5 was reported by 6 months. All pain was effectively controlled using medication only. This preliminary study indicates that RFA with PKP is a feasible minimally invasive spinal approach for treatment of thoracolumbar vertebral metastasis patients, thus meriting further exploration for spinal metastases treatment.

In theory, RFA with PKP may be associated with similar complication risks as are other conventional vertebrae cementation techniques, which pose a real risk of serious complications and even death due to bone cement leakage \[[@b15-medscimonit-20-556]\]. Zhao et al. \[[@b22-medscimonit-20-556]\] suggested that a careful selection of patients, appropriate bone cement viscosity, proper bone cement amounts, and precise location of bone cement injections all contribute to successful operations. These parameters may account for the wide variation in success rates of PKP techniques among different studies \[[@b23-medscimonit-20-556]\], and appropriate selection of these parameters in the current study may have contributed to the good overall results. Thus, further study will be required to determine the most appropriate parameters and patient eligibility criteria for wide implementation of RFA with PKP.

The integrity of the vertebral posterior cortex provides an important safeguard to prevent spinal cord injury \[[@b23-medscimonit-20-556]\]. Implementation of RFA with PKP has been controversial due to the fear of adverse effects of spinal bone cement extraversion into this space \[[@b15-medscimonit-20-556]\]. Nakatsuka et al. \[[@b24-medscimonit-20-556]\] reported that RFA treatment of vertebral metastases produced notable complications in almost one-quarter of patients, including nerve damage and sciatica, and high postoperative pain. Furthermore, this study also reported that RFA could result in incomplete paraplegia and nerve root irritation immediately following surgery, though all symptoms were alleviated by rehabilitation therapy \[[@b24-medscimonit-20-556]\]. Conversely, the outcomes reported in the present study are much more positive. To achieve these good results, careful attention was paid to the positioning of the needle, with an optimal placement of no closer than 1 cm from any important nerves or blood vessels \[[@b25-medscimonit-20-556]\]. Additionally, it has been suggested that temperature ranges should be carefully controlled at 42°C, never exceeding 43°C \[[@b26-medscimonit-20-556]\]. Notably, this strategy allows the protective posterior cortex to form a natural thermal insulator, crucial for the protection of the structure around the vertebral body \[[@b27-medscimonit-20-556]\]. Thus, pending further large-scale investigation, we recommend these parameters.

In addition, no balloon leakage was observed in the present study, unlike previous studies. Garfin et al. \[[@b28-medscimonit-20-556]\] reported that a major complication of PKP procedures in spinal metastases was cement leakage from the balloon, compressing surrounding blood vessels, nerves, and vital organs, and they reported a balloon leakage rate of 5--8% with 2--3% of affected patients requiring additional decompression surgery. Thus, the present study employed a technique in which balloon inflation, bone cement injection volume, and procedural timing was carefully controlled during surgery to prevent posterior cortex injury to the vertebral body. Previously, it has also been reported that CT guidance could significantly improve PKP outcomes and reduce complications, including cement leakage \[[@b29-medscimonit-20-556]\]. Thus, the present study used these best-practice techniques, demonstrating that current limitations of PKP surgery may be due to technical failures by the operator rather than inappropriateness of the PKP intervention *per se*. In fact, it is possible that many more patients could be eligible for minimally invasive PKP intervention, as well as those who are currently treated with more invasive surgical alternatives, necessitating better standardisation of PKP and interventionist training.

In the present study, RFA with PKP rapidly and effectively alleviated the pain associated with vertebral compression due to spinal metastases in a variety of cancer types. However, no study has assessed the combination of these 2 procedures, making comparisons with previous studies difficult. Nevertheless, these findings are consistent with a report by Dupuy et al. \[[@b27-medscimonit-20-556]\] indicating the effectiveness of RFA treatment for easing pain in bone metastases patients. Additionally, a recent clinical study by Callstrom et al. \[[@b30-medscimonit-20-556]\] confirmed that RFA treatment was safe for patients with severe pain caused by bone metastases, and that it was able to significantly alleviate pain. While RFA is effective for treating local lesions in other areas of the body, greater consideration of the specific biological characteristics of the tumor are required for treating spinal metastasis to ensure maximum safety and efficacy. A previous meta-analysis of PKP studies showed that PKP was associated with reduced pain and improved functional outcomes; balloon PKP also improved vertebral height loss and spinal deformity \[[@b31-medscimonit-20-556]\]. Furthermore, the benefits of PKP were demonstrated to be superior to classical nonsurgical treatments of vertebral metastases \[[@b32-medscimonit-20-556]\]. As for classical surgical approaches such as radical resection, no studies have compared resection, PKP, and RFA in vertebral metastasis patients. However, some studies showed promising results of tumor curettage followed by stabilization using bone grafting or methylmethacrylate \[[@b33-medscimonit-20-556],[@b34-medscimonit-20-556]\]. This approach provided outcomes that were comparable with the present studies, but postoperative complications were more common.

RFA intervention and RFA with PKP treatments improve the quality of life by alleviating symptoms of vertebral compression (palliative treatment), but do not actually cure cancer in the spine \[[@b35-medscimonit-20-556],[@b36-medscimonit-20-556]\]. Additionally, the positive findings of this relatively small study may be attributable to other factors, such as patient selection and operator experience, which are difficult to quantify. Furthermore, it is unknown if metastases from different primary tumor types may affect the response to treatments. Therefore, future studies should focus on only 1 tumor type. Thus, further large-scale clinical studies will be required to confirm these findings. However, these results do provide a positive first step toward improving palliative care for spinal metastasis patients.

Conclusions
===========

The present study demonstrated that RFA with PKP using CT-guided and balloon-inflated surgical spaces facilitated bone cement filling with no complications in 26 patients with thoracolumbar vertebral spinal metastases. Thus, RFA with PKP with the appropriate parameters of bone cement viscosity, needle positioning, bone cement volume, and temperature could alleviate the pain caused by tumors and restore vertebral height and stability. Thus, we recommend that this approach could be considered for treatment of spinal metastases, although further standardization of surgical methods and patient eligibility criteria are required to ensure a safe and effective treatment.
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![RFA and PVP procedure. (**A**) RFA umbrella electrode; (**B**) vertebral lesions treated with RFA; (**C**) vertebral formation by balloon; (**D**) bone cement injected into T~11~; (**E**) bone cement injected into L~1~.](medscimonit-20-556-g001){#f1-medscimonit-20-556}

![T~11~ and L~1~ metastasis from breast cancer before and after RFA+PKP treatment. (**A**) ECT scan; (**B**) sagittal MRI; (**C**) T~11~ axial MRI; (**D**) L~1~ axial MRI; (**E**) X-ray showing the vertebrae after RFA+PKP, more precisely the bone cement in the inferior articular process of the vertebra.](medscimonit-20-556-g002){#f2-medscimonit-20-556}

![Imaging of thoracolumbar metastatic tumors representing changes in vertebral height before and after treatment.](medscimonit-20-556-g003){#f3-medscimonit-20-556}

![Changes in mean preoperative and postoperative VAS. \* *P*\<0.01 *vs.* baseline.](medscimonit-20-556-g004){#f4-medscimonit-20-556}

###### 

Patient general information and preoperative and postoperative VAS score.

  Patient   Age            Gender                                                     Primary cancer                Follow-up (months)   Lesion no.   Location       Preoperative VAS   Postoperative VAS   Analgesic                                           
  --------- -------------- ---------------------------------------------------------- ----------------------------- -------------------- ------------ -------------- ------------------ ------------------- ------------ ------------ ------------ ------------ ----------------------------------------------------------
  1         62             M                                                          Prostate                      18                   3            L~2~, L~4~     6                  5                   2            2            2            3            U
  2         54             M                                                          Liver                         6                    2            T~11~, T~12~   7                  6                   3            3            2            3            U
  3         43             F                                                          Lymphoma                      3                    2            L~1~           9                  7                   4            4            3            2            N
  4         41             F                                                          Mesenchymal malignant tumor   4                    2            L~1~           6                  6                   2            3            2            3            N
  5         70             M                                                          Prostate                      9                    2            L~2~           9                  8                   4            3            3            2            U
  6         37             M                                                          Sacrum                        8                    2            L~4~, S~1~     7                  7                   2            2            2            3            N
  7         75             M                                                          Sacrum                        7                    2            L~5~, s~1~     8                  8                   3            3            2            2            U
  8         32             F                                                          Breast                        6                    2            L~4~, L~5~     7                  8                   2            2            2            3            U
  9         64             F                                                          Breast                        8                    2            T~11~, L~1~    7                  7                   5            4            3            2            U
  10        62             F                                                          Lung                          7                    1            T~12~, L~2~    8                  6                   5            3            4            3            N
  11        57             M                                                          Prostate                      5                    1            L~2~           8                  8                   4            5            3            4            U
  12        68             F                                                          Thyroid                       14                   2            T~11~          8                  7                   5            3            3            4            N
  13        69             M                                                          Prostate                      13                   1            L~4~           7                  5                   5            3            2            2            U
  14        46             F                                                          Breast                        12                   1            L~3~           8                  6                   7            4            4            3            N
  15        58             F                                                          Breast                        10                   1            T~12~          6                  5                   4            3            2            2            U
  16        59             F                                                          Esophagus                     8                    2            L~2~, L~3~     6                  7                   6            5            3            4            U
  17        63             M                                                          Adenocarcinoma                13                   2            L~4~           7                  6                   6            5            2            2            U
  18        58             M                                                          Kidney                        7                    1            S~1~           8                  7                   5            4            4            4            N
  19        65             F                                                          Kidney                        5                    2            L~1~, L~2~     8                  8                   6            3            4            3            U
  20        64             F                                                          Breast                        7                    2            T~12~          9                  5                   6            3            2            2            N
  21        55             F                                                          Lymphoma                      4                    2            L~4~           7                  6                   5            5            3            3            N
  22        80             M                                                          Prostate                      9                    1            T~12~          8                  7                   6            4            4            2            N
  23        57             M                                                          Liver                         5                    2            L~2~, T~12~    10                 8                   5            5            2            3            N
  24        69             M                                                          Lung                          6                    1            L~4~           8                  6                   6            4            3            5            N
  25        70             F                                                          Lung                          6                    2            T~11~, L~2~    8                  7                   6            4            2            3            U
  26        64             F                                                          Breast                        16                   1            T~12~, L~1~    10                 6                   7            5            4            5            N
  Total     59.31± 11.62   12:14[\*](#tfn2-medscimonit-20-556){ref-type="table-fn"}                                 8.31 ±3.87           1.68 ±0.56                  7.69± 1.12         6.62± 1.02          4.65± 1.55   3.62± 0.98   2.77± 0.82   2.96± 0.92   12:14[\*](#tfn2-medscimonit-20-556){ref-type="table-fn"}

D -- day; w -- week; m -- month; N -- not used; U -- used.

M: F or U: N.
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